Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Forum Members (as of December 31, 2011) Membership in the Forum includes a diverse range of stakeholders from multiple sectors, including government, the pharmaceutical and biotechnology industries, academic health centers, and patient groups. Jeffrey Drazen (Co-Chair) Elaine Gallin Michael Rosenblatt New England Journal of Medicine QE Philanthropic Advisors Merck & Co., Inc. Steven Galson (Co-Chair) Harry Greenberg Janet Shoemaker Amgen Inc. Stanford University School of Medicine American Society for Microbiology Margaret Anderson Stephen Groft Ellen Sigal FasterCures NIH Office of Rare Disease Research Friends of Cancer Research Hugh Auchincloss Anthony Hayward Elliott Sigal National Institute of Allergy and National Center for Research Bristol-Myers Squibb Infectious Diseases Resources Nancy Sung Leslie Benet Lynn Hudson Burroughs Wellcome Fund University of California, San Critical Path Institute Janet Tobias Francisco Annalisa Jenkins Ikana Media and Mount Sinai School Ann Bonham Merck Serono S.A. of Medicine Association of American Medical Michael Katz Joanne Waldstreicher Colleges March of Dimes Foundation Johnson & Johnson Linda Brady Petra Kaufmann Janet Woodcock National Institute of Mental Health National Institute of Neurological FDA Center for Drug Evaluation Robert Califf Disorders and Stroke and Research Duke University Medical Center Jack Keene Scott Campbell Duke University Medical Center Foundation for the NIH Ronald Krall C. Thomas Caskey University of Pennsylvania Membership Baylor College of Medicine Freda Lewis-Hall Patient Gail Cassell Pfizer Inc. Advocacy Harvard Medical School Department Mark McClellan Government of Social and Global Medicine Foundations and 8% The Brookings Institution (visiting) Associations 20% Carol Mimura 13% Peter Corr University of California, Biotech/Other Celtic Therapeutics, LLLP Berkeley Industry 5% Andrew Dahlem Elizabeth (Betsy) Myers Eli Lilly & Co. Doris Duke Charitable 17% 22% James Doroshow Foundation Pharma National Cancer Institute John Orloff Academic Gary Filerman Novartis Pharmaceuticals 15% Health Centers Atlas Health Foundation Corporation Miscellaneous Garret FitzGerald Amy Patterson Nonprofit University of Pennsylvania School NIH Office of the Director of Medicine
Forum Sponsorship Forum Members and Sponsorship (as of December 31, 2011) Financial support for the Forum is derived from private foundations, government agencies, industry sponsors, and nonprofit associations. Private Foundations Burroughs Wellcome Fund Doris Duke Charitable Foundation Other Nonprofit Organizations American Society for Microbiology Association of American Medical Colleges Critical Path Institute Faster Cures Foundation for the National Institutes of Health Friends of Cancer Research Government Sponsors Food and Drug Administration National Cancer Institute (National Institutes of Health) National Center for Research Resources (National Institutes of Health) National Institute of Allergy and Infectious Diseases (National Institutes of Health) National Institute of Mental Health (National Institutes of Health) National Institute of Neurological Disorders and Stroke (National Institutes of Health) Office of Rare Diseases Research (National Institutes of Health) Industry Sponsors Amgen Inc. Bristol-Myers Squibb Celtic Therapeutics, LLLP Eli Lilly & Co. GlaxoSmithKline Johnson & Johnson Merck & Co., Inc. 13% Novartis Pharmaceuticals Corporation Pfizer Inc. 24% 63%
About the Forum on Drug Discovery, Development, and Translation About the Institute of Medicine The IOMâs Forum on Drug Discovery, Development, and Translation The Institute of Medicine was established was created in 2005 by the IOMâs Board on Health Sciences Policy in 1970 by the National Academy of Sciences to provide a unique platform for dialogue and collaboration among to secure the services of eminent members of thought leaders and stakeholders in government, academia, industry, appropriate professions in the examination foundations, and patient advocacy. The Forum brings together lead- of policy matters pertaining to the health of ers from private-sector sponsors of biomedical and clinical research, the public. The Institute acts under the federal agencies sponsoring and regulating biomedical and clinical responsibility assigned to the National Academy research, the academic community, and consumers, and in doing so of Sciences by its congressional charter to serve serves to educate the policy community about issues where science as an adviser to the federal government and, and policy intersect. upon its own initiative, to identify issues needing attention in the areas of medical care, research, The Forum convenes several times each year to identify and discuss and education. key problems and strategies in the discovery, development, and translation of drugs. To supplement the perspectives and expertise Forum Staff of its members, the Forum also holds public workshops to engage a Anne B. Claiborne, J.D., M.P.H. wide range of experts, members of the public, and the policy com- Forum Director munity in discussing areas of concern in the science and policy of Rita S. Guenther, Ph.D. drug development. The Forumâs public meetings focus substantial Program Officer public attention on critical areas of drug development. Proceedings Rebecca A. English, M.P.H. and speaker presentations are disseminated to the public through Associate Program Officer published summaries and the Forum website. For more information Elizabeth F. C. Tyson about the Forum on Drug Discovery, Development, and Translation, Research Associate please visit our website at: www.iom.edu/drug. Robin Guyse Senior Program Assistant Board on Health Sciences Policy Andrew M. Pope, Ph.D. Director The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The mission of the Institute of Medicine embraces the health of people everywhere.